Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10548
Country/Region: Ethiopia
Year: 2016
Main Partner: Jimma University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $453,246 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Health Systems Strengthening (OHSS) $134,268
Sexual Prevention: Other Sexual Prevention (HVOP) $16,904
Treatment: Adult Treatment (HTXS) $250,639
Treatment: Pediatric Treatment (PDTX) $51,435
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 27
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 20
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 30
GEND_GBV Number of people receiving post-GBV care 2017 50
HRH_PRE By Graduates: Doctors 2017 141
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 141
HRH_PRE Sum of Graduates disaggregates 2017 141
PP_PREV Aggregated Age/sex: <15 Female 2017 20
PP_PREV Aggregated Age/sex: <15 Male 2017 10
PP_PREV Aggregated Age/sex: 15+ Female 2017 630
PP_PREV Aggregated Age/sex: 15+ Male 2017 340
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,000
PP_PREV Total number of people in the target population 2017 1,100
TX_CURR Aggregated Age/Sex: <15 Female 2017 225
TX_CURR Aggregated Age/Sex: <15 Male 2017 229
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,748
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,654
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 4,856
TX_CURR Sum of Aggregated Age/Sex <15 2017 454
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 4,402
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 4,856
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 73
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 49
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 739
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 440
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,301
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 1,301
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 3,148
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 2,518
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 116
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 119
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 1,425
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 858
TX_PVLS Numerator: Indication: Routine 2017 2,014
TX_PVLS Numerator: Indication: Targeted 2017 504
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 146
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 148
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 1,782
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,072
TX_PVLS_den Denominator: Indication: Routine 2017 2,518
TX_PVLS_den Denominator: Indication: Targeted 2017 630
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 131
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 71
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 227
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 247
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 15
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 142
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 78
Cross Cutting Budget Categories and Known Amounts Total: $140,768
Human Resources for Health $134,268
Gender: Gender Based Violence (GBV) $6,500
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation